SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-010389
Filing Date
2021-08-05
Accepted
2021-08-05 07:31:25
Documents
77
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20210630x10q.htm   iXBRL 10-Q 1934113
2 EX-10.1 acrs-20210630xex10d1.htm EX-10.1 15593
3 EX-31.1 acrs-20210630xex31d1.htm EX-31.1 15674
4 EX-31.2 acrs-20210630xex31d2.htm EX-31.2 15680
5 EX-32.1 acrs-20210630xex32d1.htm EX-32.1 9512
  Complete submission text file 0001558370-21-010389.txt   8109927

Data Files

Seq Description Document Type Size
6 EX-101.SCH acrs-20210630.xsd EX-101.SCH 49619
7 EX-101.CAL acrs-20210630_cal.xml EX-101.CAL 51940
8 EX-101.DEF acrs-20210630_def.xml EX-101.DEF 181989
9 EX-101.LAB acrs-20210630_lab.xml EX-101.LAB 527600
10 EX-101.PRE acrs-20210630_pre.xml EX-101.PRE 358220
11 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20210630x10q_htm.xml XML 1593456
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 211146340
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences